Osteoboost Presents Clinical Trial Data Demonstrating High Adherence and Usability for Osteopenia at ENDO 2025
Redwood City, CA, July 14, 2025 – A 12-month randomized, sham-controlled clinical trial has found that Osteoboost, the first and only FDA-cleared prescription medical device for low bone density, achieved a notably high patient use adherence rate and high usability scores among postmenopausal women. These results will be presented at ENDO 2025, the largest and most prominent endocrinology conference. The poster presentation highlights how the device offers an easy-to-use, non-pharmacological alternative for patients with low bone density.
The study enrolled postmenopausal women with osteopenia and randomized participants 1:1 to receive either active vibration therapy via the Osteoboost device or a sham device that mimicked treatment without delivering therapeutic vibration. Subjects were instructed to use the device for 30 minutes per day, at least five days per week, while engaging in activities of daily living.
Key findings include:
- 88% of participants completed the full 12-month trial
- 82% adherence rate to the recommended regimen
- 72% of users found the device easy to use
- Participants said it fit easily into daily routines, with a rating of 8 out of 10
Postmenopausal women face a rapid decline in bone density and strength, increasing their risk for fractures. Pharmacological treatments often suffer from low adherence and high discontinuation rates. Osteoboost offers a drug-free, at-home treatment—delivering targeted mechanical stimulation to the spine and hips during routine daily activities like walking, cooking, and even watching TV.
When comparing adherence results to other home-use medical devices, Osteoboost proved to be convenient and easy to continue using in the long-term, empowering patients to take control of their bone health. These results supplement previously reported data from the same trial, which showed that targeted vibration therapy significantly reduced loss of vertebral bone strength and density compared to sham treatment.
“These findings reinforce just how easily Osteoboost fits into real lives,” said Michael Jaasma, co-founder and Chief Scientific Officer at Osteoboost. “We’re empowering patients to manage their own bone health proactively. Postmenopausal women were able to use the device comfortably and consistently by incorporating it into their daily routines without disruption, which is critical for any long-term treatment as it supports regular use.”
Osteoboost delivers low-magnitude, targeted vibration therapy to the spine and hips through a wearable belt, offering a low-burden, home-based intervention. The combination of high adherence, patient-reported usability, and previously demonstrated efficacy positions Osteoboost as a promising alternative to pharmacologic treatment for appropriate patients.
The poster can be downloaded here.
Osteoboost announced nationwide availability in May and has begun shipping devices. The company also recently secured its sixth U.S. patent, further strengthening its intellectual property portfolio and leadership in vibration technology.
About Osteoboost
Osteoboost Health is a Redwood City-based medical technology company developing innovative, non-invasive, and science-backed solutions for people with low bone density. Osteoboost is backed by leading investors, including Esplanade Ventures, Terumo Medical Corporation, Ambit Health Ventures, Portfolia, Astia Angels, and Golden Seeds. For more information, including the Instructions for Use, please visit https://osteoboost.com/.
Media Contact
VSC for Osteoboost
osteoboost@vsc.co
